The purpose of the study is to assess how effective ATRA and tailored radiotherapy are in treating patients with localized squamous cell carcinoma of the head and neck. Participants in the study will receive either standard or reduced-target volume radiotherapy, with or without ATRA. The study will also involve the use of other medications, including cetuximab and cisplatin, which are commonly used in cancer treatment. Cetuximab is a protein-based medication, while cisplatin is a chemical compound used to stop the growth of cancer cells.

Throughout the study, participants will receive treatments over a period of time and will be monitored for their response to the therapy. The study aims to understand the impact of these treatments on the survival and quality of life of patients, as well as any potential side effects. The ultimate goal is to improve treatment strategies for head and neck cancer, providing better outcomes for patients.

The trial will involve several medications, including fluorouracil, carboplatin, and cisplatin, which are types of chemotherapy drugs. These medications are given to help stop the growth of cancer cells. The purpose of the study is to see if the new treatment plan can improve the overall survival of patients with this type of cancer. Participants in the study will receive these treatments over a period of time, and their health will be monitored to see how well the treatment works.

The study will follow a specific course where participants will receive the treatments through intravenous infusion, which means the medication is given directly into a vein. The trial aims to find out if the new treatment plan can help patients live longer and control the cancer better than the current standard treatments. The study will also look at other factors, such as how the treatment affects the quality of life and any side effects that may occur. The ultimate goal is to find a more effective way to treat this type of cancer and improve the lives of those affected by it.

The purpose of the study is to find out if this fluorescent method can help surgeons better identify and remove cancerous tissue during a surgery called a total laryngectomy or pharyngectomy. This is a procedure where the affected parts of the throat are removed. The study will involve giving the medication through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. The goal is to see if the glowing effect can help doctors distinguish cancerous tissue from healthy tissue more effectively.

Participants in the study will receive the medication before their surgery, and doctors will use a special camera to see the glowing effect during the operation. The study will help determine if this method is practical and useful for improving the accuracy of cancer surgeries in the throat area. The trial is expected to continue until the end of 2025, with recruitment starting in late 2024.

The treatment involves taking Afatinib in the form of film-coated tablets, which are taken orally. The study will compare the effects of different doses of Afatinib to see how well it works in controlling the cancer and improving the quality of life for patients. Participants will be monitored for any side effects and how their cancer responds to the treatment over a period of time.

The purpose of this study is to gather information on the effectiveness of Afatinib in treating cancers associated with Fanconi anemia. The study will also look at how long the treatment effects last, the overall survival of patients, and any changes in their health-related quality of life. This information will help in understanding the potential benefits and risks of using Afatinib for this specific group of patients.

The purpose of this research is to determine if using both pembrolizumab and lenvatinib together works better than using pembrolizumab alone in preventing cancer from returning. Pembrolizumab is given through an intravenous infusion into a vein, while lenvatinib is taken as oral capsules. The treatment period may last up to 47 weeks.

The study will include patients whose cancer cells have a specific characteristic called PD-L1, which is a protein found on some cancer cells. Patients will receive regular medical check-ups throughout the study period to monitor their health and evaluate how well the treatment is working. The medications being studied are designed to help the body’s immune system fight cancer cells.

Participants in the study will receive either the combination of these chemotherapy drugs followed by radiotherapy or a treatment where cisplatin is given at the same time as radiotherapy. Radiotherapy is a treatment that uses high-energy rays to target and destroy cancer cells. The purpose of the study is to determine which treatment method is better at helping patients survive without losing the function of their larynx or needing major surgery like a total laryngectomy, which is the removal of the larynx.

The study will take place over several months, and participants will be monitored for their response to the treatment, any side effects they experience, and their overall health. The goal is to find the most effective way to treat this type of cancer while preserving the patient’s ability to speak and swallow normally. The study will also look at the overall survival rates and the quality of life of the participants during and after the treatment.

Participants in the study will receive either the standard treatment or the standard treatment plus pembrolizumab. The study will monitor patients over a period of 24 to 48 months to see how many can avoid laryngectomy and how long they live without the cancer returning. The study will also look at the quality of swallowing, which is an important aspect of life for patients with throat cancer. Other medications that may be used in the study include clindamycin, an antibiotic, and dexamethasone, an anti-inflammatory drug, to manage side effects or other conditions.

The purpose of this study is to improve the treatment outcomes for patients with advanced head and neck cancer by potentially offering a treatment option that preserves the larynx and improves survival rates. The study will help determine if pembrolizumab can be a beneficial addition to the current treatment protocol for these types of cancer.